Immediate reactions after mRNA SARS-CoV-2 vaccination

Affiliations

¹ Division of Clinical Immunology and Allergy (Jeimy), Department of Medicine, Western University, London, Ont.; Division of Allergy and Immunology (Wong), Department of Pediatrics, The University of British Columbia, Vancouver, BC; Division of Clinical Immunology and Allergy (Song), Department of Medicine, University of Toronto, Toronto, Ont. samira.jeimy@lhsc.on.ca.
² Division of Clinical Immunology and Allergy (Jeimy), Department of Medicine, Western University, London, Ont.; Division of Allergy and Immunology (Wong), Department of Pediatrics, The University of British Columbia, Vancouver, BC; Division of Clinical Immunology and Allergy (Song), Department of Medicine, University of Toronto, Toronto, Ont.

Samira Jeimy et al. CMAJ. 2021.

. 2021 Dec 6;193(48):E1842.

doi: 10.1503/cmaj.211581. Epub 2021 Nov 12.

¹ Division of Clinical Immunology and Allergy (Jeimy), Department of Medicine, Western University, London, Ont.; Division of Allergy and Immunology (Wong), Department of Pediatrics, The University of British Columbia, Vancouver, BC; Division of Clinical Immunology and Allergy (Song), Department of Medicine, University of Toronto, Toronto, Ont. samira.jeimy@lhsc.on.ca.
² Division of Clinical Immunology and Allergy (Jeimy), Department of Medicine, Western University, London, Ont.; Division of Allergy and Immunology (Wong), Department of Pediatrics, The University of British Columbia, Vancouver, BC; Division of Clinical Immunology and Allergy (Song), Department of Medicine, University of Toronto, Toronto, Ont.

No abstract available

Conflict of interest statement

Competing interests: None declared.

1. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US: December 14, 2020–January 18, 2021. JAMA 2021;325:1101–2. - PMC - PubMed
1. Krantz MS, Kwah JH, Stone CA, Jr, et al. . Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern Med 2021;181:1530–3. - PMC - PubMed
1. Mark C, Gupta S, Punnett A, et al. . Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer 2021;68:e29295. - PMC - PubMed
1. Wolfson AR, Robinson LB, Li L, et al. . First dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract 2021;9:3308–20.e3. - PMC - PubMed
1. Warren CM, Snow TT, Lee AS, et al. . Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open 2021;4:e2125524. - PMC - PubMed